We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
Read MoreHide Full Article
OPKO Health, Inc. (OPK - Free Report) announced that it has initiated a phase II study — REsCue — to evaluate its vitamin D3 analog drug, Rayaldee, as a potential treatment for mild-to-moderate COVID-19.
The study will enroll 160 patients including patients with stage 3 or 4 chronic kidney disease (“CKD”), who are at higher risk of developing more severe illness.
The REsCue study will evaluate a four-week treatment regimen of Rayaldee in COVID-19 outpatients followed by two weeks of follow-up. Patients will receive 300 mcg per day on first three days of treatment followed by 60 mcg per day for the rest of the treatment period or a placebo. The primary endpoints of the study are to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL, and time to resolution of COVID-19 symptoms. The study’s secondary endpoints include new cases of emergency room or urgent care visits, patient’s oxygen saturation below 94%, any need for and duration of hospitalizations, requirement for mechanical ventilation, mortality rate, and severity and duration of illness evidenced by quality-of-life measures.
The company anticipates top-line data from the phase II study by the end of 2020. The company remains hopeful about its drug as potential treatment for COVID-19 as several independent studies have demonstrated that there is a correlation between vitamin D status and COVID-19 risk and severity.
Please note that Rayaldee is approved for treating secondary hyperparathyroidism in adults with stage 3 or 4 CKD and vitamin D insufficiency.
Shares of OPKO Health have gained 114.3% so far this year compared with the industry’s increase of 16.8%.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. However, several pharma companies are developing treatments/antibodies for different stages of COVID-19. Leading among them is Gilead’s (GILD) Veklury (remdisivir), which has already received an emergency use authorization from the FDA for treating all hospitalized patients with COVID-19.
Earlier this week, Eli Lilly (LLY - Free Report) and partner Incyte (INCY - Free Report) announced that a phase III study evaluating their rheumatoid arthritis drug, Olumiant, in combination with remdesivir for hospitalized patients with COVID-19 infections met the primary endpoint of reduction of time to recovery in comparison with remdesivir alone.
Roche (RHHBY - Free Report) is conducting a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir in hospitalized patients with severe COVID-19 pneumonia.
We note that Regeneron also initiated studies on REGN-COV2, a novel investigational antibody cocktail treatment designed to prevent and treat the SARS-CoV-2 virus this month. Moreover, Amgen’s Otezla is being investigated as a potential immunomodulatory treatment in patients hospitalized with SARS-CoV-2 infection in multiple COVID-19 platform trials. Vanda Pharmaceuticals' is evaluating its pipeline candidate, tradipitant, for treating COVID-19 pneumonia.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Shutterstock
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
OPKO Health, Inc. (OPK - Free Report) announced that it has initiated a phase II study — REsCue — to evaluate its vitamin D3 analog drug, Rayaldee, as a potential treatment for mild-to-moderate COVID-19.
The study will enroll 160 patients including patients with stage 3 or 4 chronic kidney disease (“CKD”), who are at higher risk of developing more severe illness.
The REsCue study will evaluate a four-week treatment regimen of Rayaldee in COVID-19 outpatients followed by two weeks of follow-up. Patients will receive 300 mcg per day on first three days of treatment followed by 60 mcg per day for the rest of the treatment period or a placebo. The primary endpoints of the study are to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL, and time to resolution of COVID-19 symptoms. The study’s secondary endpoints include new cases of emergency room or urgent care visits, patient’s oxygen saturation below 94%, any need for and duration of hospitalizations, requirement for mechanical ventilation, mortality rate, and severity and duration of illness evidenced by quality-of-life measures.
The company anticipates top-line data from the phase II study by the end of 2020. The company remains hopeful about its drug as potential treatment for COVID-19 as several independent studies have demonstrated that there is a correlation between vitamin D status and COVID-19 risk and severity.
Please note that Rayaldee is approved for treating secondary hyperparathyroidism in adults with stage 3 or 4 CKD and vitamin D insufficiency.
Shares of OPKO Health have gained 114.3% so far this year compared with the industry’s increase of 16.8%.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. However, several pharma companies are developing treatments/antibodies for different stages of COVID-19. Leading among them is Gilead’s (GILD) Veklury (remdisivir), which has already received an emergency use authorization from the FDA for treating all hospitalized patients with COVID-19.
Earlier this week, Eli Lilly (LLY - Free Report) and partner Incyte (INCY - Free Report) announced that a phase III study evaluating their rheumatoid arthritis drug, Olumiant, in combination with remdesivir for hospitalized patients with COVID-19 infections met the primary endpoint of reduction of time to recovery in comparison with remdesivir alone.
Roche (RHHBY - Free Report) is conducting a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir in hospitalized patients with severe COVID-19 pneumonia.
We note that Regeneron also initiated studies on REGN-COV2, a novel investigational antibody cocktail treatment designed to prevent and treat the SARS-CoV-2 virus this month. Moreover, Amgen’s Otezla is being investigated as a potential immunomodulatory treatment in patients hospitalized with SARS-CoV-2 infection in multiple COVID-19 platform trials. Vanda Pharmaceuticals' is evaluating its pipeline candidate, tradipitant, for treating COVID-19 pneumonia.
OPKO Health, Inc. Price
OPKO Health, Inc. price | OPKO Health, Inc. Quote
Zacks Rank
OPKO Health currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>